TICKERNERD
Menu
AMRXAMRXHealthcare · Drug Manufacturers - Specialty & Generic

AMRX Stock Forecast: Amneal Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$18
+5.10% on the day

The 4 Wall Street analysts covering Amneal Pharmaceuticals, Inc. hold a median 12-month price target of $21 — +15.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.3B
Ticker Nerd rank
79 / 100
Median analyst target
$21
Analysts covering
4
Total return, dividends reinvested
1W
+0.1%
1M
+8.7%
YTD
+44.0%
1Y
+93.3%
From 52W high
−5.0%
From 52W low
+96.0%
$9
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amneal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
92
Value
90
Momentum
88
Volatility
83
Growth
80
Revisions
70
Accruals
32
Size
22
Issuance
17

Quality (92): The business earns solid, repeatable profits on what it owns.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Oct 25Jan 26Apr 26Jul 26AMRXHigh $25Median $21Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $16Median $21High $25

The green dot is the last close — the median target sits +15.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Aug 2026UBSMaintainsBuy$23 → $25
15 July 2026UBSMaintainsBuy$19 → $23
15 July 2026UBSMaintainsBuy—
20 May 2026BarclaysMaintainsOverweight$15 → $16
20 May 2026BarclaysMaintainsOverweight—
17 Apr 2026UBSInitiatesBuy—
2 Mar 2026Truist SecuritiesMaintainsBuy—
9 Dec 2025BarclaysInitiatesOverweight—
31 Oct 2025Piper SandlerReiteratesOverweight—
16 Sept 2025JP MorganMaintainsOverweight—
3 Mar 2025BarclaysMaintainsOverweight—
24 Feb 2025JP MorganUpgradeOverweight—
11 Nov 2024Piper SandlerMaintainsOverweight—
2 Oct 2024Truist SecuritiesMaintainsBuy—
6 Sept 2024JP MorganUpgradeNeutral—
13 Aug 2024BarclaysMaintainsOverweight—
12 Aug 2024Truist SecuritiesMaintainsBuy—
6 May 2024Goldman SachsMaintainsBuy—
6 May 2024Truist SecuritiesReiteratesBuy—
21 Mar 2024Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AMRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.8%
Analysts raising
0
Analysts cutting
1
Fundamentals

Amneal Pharmaceuticals, Inc. (AMRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.3×

Cheaper than 22% of US stocks

Price / sales
2.0×

Cheaper than 53% of US stocks

Price / book
176.2×

Cheaper than 1% of US stocks

EV / EBITDA
12.4×

Cheaper than 31% of US stocks

Growth & margins
Revenue growth (YoY)
9.9%

Higher than 52% of US stocks

Earnings growth (YoY)
157.2%

Higher than 88% of US stocks

Gross margin
42.0%

Higher than 53% of US stocks

Operating margin
18.3%

Higher than 77% of US stocks

Net margin
5.0%

Higher than 60% of US stocks

Returns & dividend
Return on equity
613.0%

Higher than 99% of US stocks

Return on assets
8.6%

Higher than 89% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AMRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMRXAmneal Pharmaceuticals, Inc.$6.3B
79
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
LQDALiquidia Corp.$6.4B
78
LNTHLantheus Holdings, Inc.$6.5B
88
HIMSHims & Hers Health, Inc.$6.6B
17
INDVIndivior Pharmaceuticals, Inc.$4.6B
98
ALKSAlkermes Plc$8.1B
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amneal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMRX news & analysis

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Zacks Investment Research · 12 Aug 2026neutral

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, though Rytary erosion and execution risks remain concerns. Zacks Investment Research highlights the company's improved growth outlook alongside persistent operational challenges.

Why it matters — AMRX watchers would care because the company's raised guidance and expanded pipeline signal growth potential, while Rytary erosion and execution risks could affect near-term performance.

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

Zacks Investment Research · 12 Aug 2026neutral

Zacks reports that Amneal Pharmaceuticals' (AMRX) Kashiv deal creates an integrated biosimilars platform. The report notes that integration, regulatory execution, and product uptake remain key factors for the deal's success.

Why it matters — An AMRX watcher would care because this deal could position biosimilars as a major growth engine for the company, making its execution in integration and regulatory approvals important to monitor.

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Zacks Investment Research · 12 Aug 2026neutral

Amneal Pharmaceuticals' stock has risen 44.8% over the past three months, according to Zacks Investment Research, and the rally now faces a test as upcoming earnings, product launches, and pipeline progress contend with Rytary erosion and a higher historical valuation.

Why it matters — AMRX watchers would care because the stock's recent gains may be challenged by Rytary revenue erosion and a higher valuation, making upcoming earnings and pipeline developments key to watch.

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research · 11 Aug 2026positive

Zacks Investment Research notes that Amneal (AMRX) qualified for its "Recent Price Strength" screen, which identifies fundamentally strong stocks currently on the move. The company is presented as one of several stocks that made it through this screening process.

Why it matters — AMRX watchers would care because the stock has been recognised for recent price strength alongside strong fundamentals, which signals current market momentum worth monitoring.

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

GlobeNewsWire · 10 Aug 2026positive

Amneal Pharmaceuticals announced the completion of its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization. The company said the deal adds a major long-term growth pillar and extends its growth profile into the 2030s.

Why it matters — For AMRX watchers, this acquisition establishes an integrated global biosimilar platform that is expected to serve as a significant long-term growth driver extending into the 2030s.

FAQ

Frequently asked questions about AMRX stock

What is the AMRX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Amneal Pharmaceuticals, Inc. have a median 12-month price target of $21, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMRX stock a buy right now?

Of the 4 analysts covering Amneal Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amneal Pharmaceuticals, Inc. 79 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMRX?

As at 15 Aug 2026, Amneal Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).

Will AMRX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +15.7% from the last close, and Ticker Nerd's factor model ranks Amneal Pharmaceuticals, Inc. 79 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMRX stock forecast for 2030?

No analyst covering Amneal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.

How has AMRX stock performed over the past year?

Amneal Pharmaceuticals, Inc. returned +93.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amneal Pharmaceuticals, Inc. do?

Amneal Pharmaceuticals Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines across three reportable segments: Affordable Medicines, Specialty, and AvKARE.

What is the latest news on AMRX?

The most recent item we track (Zacks Investment Research, 12 Aug 2026): "Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?". Amneal enters the second half of 2026 with higher guidance and a broader pipeline, though Rytary erosion and execution risks remain concerns. Zacks Investment Research highlights the company's improved growth outlook alongside persistent operational challenges.

Company

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines across three reportable segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers a broad range of generic pharmaceuticals in various dosage forms and delivery systems, including complex injectables, biosimilars like denosumab referencing Prolia and XGEVA, respiratory therapies such as albuterol sulfate inhalation aerosol equivalent to PROAIR HFA, ophthalmic products like cyclosporine emulsion equivalent to RESTASIS, and iohexol injection as the first generic of Omnipaque. The Specialty segment focuses on proprietary branded pharmaceuticals targeting central nervous system disorders, such as CREXONT for Parkinson’s disease to improve motor symptom control, and endocrine therapies like UNITHROID. The AvKARE segment supplies pharmaceuticals and medical products to governmental agencies through re-packaging and wholesale distribution, emphasizing consistent care and pricing. Operating in the U.S., India, and Ireland, Amneal Pharmaceuticals Inc. supports healthcare providers, institutions, and patients with affordable and innovative treatments. Founded in 2002 and headquartered in Bridgewater, New Jersey, it plays a key role in the generics, specialty, and institutional pharmaceuticals markets.

CEO Mr. Chirag K. Patel · 8,700 employees · United States · https://www.amneal.com